Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?

Capricor Therapeutics, Inc. shares closed 58% higher at $6.65 on August 14 following an announcement that the FDA would review an amendment containing 24-month data for deramiocel, its experimental Duchenne muscular dystrophy treatment. The stock had risen as much as 94% intraday before retracing some gains. The move represented a partial recovery from earlier losses sustained after an advisory panel voted 9-3 that available evidence did not establish deramiocel’s effectiveness for Duchen